Sign In
29 May 2020 09:37
PDMR Shareholding
May 29, 2020
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on May 28th 15,800 Shares were purchased by Iain Ross, Executive Chairman of the Company, through his SIPP at £4.70 per share.
Following this purchase, Iain Ross is interested in 44,693 ordinary shares (0.05%) of the issued shared capital of the Company. The previously disclosed 25,000 shares held by Mr Ross did not include 3,893 shares that were already held in Mr Ross's SIPP and originate from his previous tenure with the Company that ended in 2010. The 44,693 ordinary shares now held by Mr Ross corrects for these previously undisclosed shares.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||
a) | Name | Iain Ross
| ||||
2. | Reason for the notification | |||||
a) | Position / status | Executive Chairman
| ||||
b) | Initial notification / Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Silence Therapeutics plc
| ||||
b) | LEI | 213800SSURRJBX85SQ91
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 5 pence each in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
| ||||
b) | Nature of the transaction | Purchase of Ordinary Shares in Silence Therapeutics plc
| ||||
c) | Prices(a) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
15,800 Ordinary Shares £74,260.00 | ||||
e) | Date of the transaction | 28 May 2020 | ||||
f) | Place of the transaction | London Stock Exchange, AIM
| ||||
Enquiries:
Silence Therapeutics plc Iain Ross, Executive Chairman Dr Rob Quinn, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
|
Tel: +44 (0) 20 7597 5970 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
Follow the stocks
